NCT01888107View on ClinicalTrials.gov

Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

347

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Risperidone Long-acting Injectable (LAI) 25 mg

Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.

DRUG

Risperidone LAI 37.5 mg

Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.

DRUG

Risperidone LAI 50 mg

Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.

All Listed Sponsors
lead

Janssen-Cilag S.p.A.

INDUSTRY

NCT01888107 - Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder | Biotech Hunter | Biotech Hunter